Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)
The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a re...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2017/5282343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564417389133824 |
|---|---|
| author | Sunghwan Suh Sun Ok Song Jae Hyeon Kim Hyungjin Cho Woo Je Lee Byung-Wan Lee |
| author_facet | Sunghwan Suh Sun Ok Song Jae Hyeon Kim Hyungjin Cho Woo Je Lee Byung-Wan Lee |
| author_sort | Sunghwan Suh |
| collection | DOAJ |
| description | The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea. |
| format | Article |
| id | doaj-art-96e8bebcb1d24a20b956286eecc55c3d |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-96e8bebcb1d24a20b956286eecc55c3d2025-02-03T01:11:09ZengWileyJournal of Diabetes Research2314-67452314-67532017-01-01201710.1155/2017/52823435282343Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)Sunghwan Suh0Sun Ok Song1Jae Hyeon Kim2Hyungjin Cho3Woo Je Lee4Byung-Wan Lee5Division of Endocrinology, Dong-A University Medical Center, Dong-A University School of Medicine, Busan, Republic of KoreaDivision of Endocrinology, Department of Internal Medicine, National Health Insurance Service, Ilsan Hospital, Ilsan, Republic of KoreaDivision of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaNovartis Korea, Seoul, Republic of KoreaDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of KoreaDivision of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of KoreaThe present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.http://dx.doi.org/10.1155/2017/5282343 |
| spellingShingle | Sunghwan Suh Sun Ok Song Jae Hyeon Kim Hyungjin Cho Woo Je Lee Byung-Wan Lee Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) Journal of Diabetes Research |
| title | Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) |
| title_full | Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) |
| title_fullStr | Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) |
| title_full_unstemmed | Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) |
| title_short | Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study) |
| title_sort | effectiveness of vildagliptin in clinical practice pooled analysis of three korean observational studies the victory study |
| url | http://dx.doi.org/10.1155/2017/5282343 |
| work_keys_str_mv | AT sunghwansuh effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy AT sunoksong effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy AT jaehyeonkim effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy AT hyungjincho effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy AT woojelee effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy AT byungwanlee effectivenessofvildagliptininclinicalpracticepooledanalysisofthreekoreanobservationalstudiesthevictorystudy |